Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Reported Tuberculosis in the United States, 2020						Print
																Related Pages
					Return to Main Menu
Table 28. Tuberculosis Cases and Incidence Rate per 100,000 Population: Reporting Areas, 2020 and 2019
See Surveillance Slides #6, #7 and #9
Table 28. Tuberculosis Cases and Case Rates per 100,000 Population: Reporting Areas, 2019 and 2018
Reporting Area
Cases
Incidence Rate
Rank According to Rate
Population Estimates
July 1, 20202020
2019
2020
2019
2020
2019**United States**
**7,174**
**8,904**
**2.2**
**2.7**
**––**
**––**
**329,484,123**Alabama
73
87
1.5
1.8
29
27
4,921,532Alaska
58
58
7.9
7.9
1
1
731,158Arizona
136
183
1.8
2.5
18
15
7,421,401Arkansas
59
64
1.9
2.1
15
18
3,030,522California
1,705
2,112
4.3
5.4
4
4
39,368,078Colorado
52
66
0.9
1.1
43
42
5,807,719Connecticut
54
67
1.5
1.9
26
24
3,557,006Delaware
17
19
1.7
1.9
21
21
986,809District of Columbia
19
24
2.7
3.4
7
8
712,816Florida
412
558
1.9
2.6
16
12
21,733,312Georgia
221
302
2.1
2.8
12
10
10,710,017Hawaii
92
99
6.5
7.0
2
2
1,407,006Idaho
8
7
0.4
0.4
50
50
1,826,913Illinois
216
326
1.7
2.6
22
14
12,587,530Indiana
92
108
1.4
1.6
33
33
6,754,953Iowa
39
52
1.2
1.6
38
32
3,163,561Kansas
37
38
1.3
1.3
36
40
2,913,805Kentucky
67
66
1.5
1.5
28
36
4,477,251Louisiana
99
88
2.1
1.9
9
22
4,645,318Maine
17
18
1.3
1.3
37
37
1,350,141Maryland
149
209
2.5
3.5
8
7
6,055,802Massachusetts
142
178
2.1
2.6
13
13
6,893,574Michigan
101
131
1.0
1.3
42
39
9,966,555Minnesota
117
148
2.1
2.6
11
11
5,657,342Mississippi
41
58
1.4
1.9
31
20
2,966,786Missouri
72
70
1.2
1.1
40
43
6,151,548Montana
4
2
0.4
0.2
51
51
1,080,577Nebraska
36
17
1.9
0.9
17
44
1,937,552Nevada
57
53
1.8
1.7
19
29
3,138,259New Hampshire
12
6
0.9
0.4
45
49
1,366,275New Jersey
245
310
2.8
3.5
6
6
8,882,371New Mexico
29
41
1.4
2.0
32
19
2,106,319New York State1
161
187
1.5
1.7
30
30
11,083,563New York City
445
559
5.4
6.7
3
3
8,253,213North Carolina
159
185
1.5
1.8
27
28
10,600,823North Dakota
10
18
1.3
2.4
34
16
765,309Ohio
130
150
1.1
1.3
41
41
11,693,217Oklahoma
67
73
1.7
1.8
23
25
3,980,783Oregon
67
70
1.6
1.7
25
31
4,241,507Pennsylvania
157
198
1.2
1.5
39
35
12,783,254Rhode Island
8
14
0.8
1.3
46
38
1,057,125South Carolina
67
80
1.3
1.6
35
34
5,218,040South Dakota
16
16
1.8
1.8
20
26
892,717Tennessee
113
129
1.6
1.9
24
23
6,886,834Texas
884
1,155
3.0
4.0
5
5
29,360,759Utah
29
27
0.9
0.8
44
46
3,249,879Vermont
3
4
0.5
0.6
49
47
623,347Virginia
169
191
2.0
2.2
14
17
8,590,563Washington
163
221
2.1
2.9
10
9
7,693,612West Virginia
13
10
0.7
0.6
47
48
1,784,787Wisconsin
35
51
0.6
0.9
48
45
5,832,655Wyoming
0
1
0.0
0.2
52
52
582,328American Samoa2
3
2
6.3
4.1
**––**
**––**
47,392Fed. States of Micronesia2
84
91
73.7
79.8
**––**
**––**
114,000Guam2
57
79
33.8
47.0
**––**
**––**
168,489Marshall Islands2
149
226
252.5
383.1
**––**
**––**
59,000Northern Mariana Islands2
39
49
75.2
94.1
**––**
**––**
51,851Puerto Rico2
27
36
0.8
1.1
**––**
**––**
3,190,410Palau2
9
6
50.0
33.3
**––**
**––**
18,000U.S. Virgin Islands2
4
2
3.8
1.9
**––**
**––**
106,290Show More
Show More1Excludes New York City.2Not ranked with the U.S. regions or included with the U.S. totals.
**Note:** Denominators for computing 2019 and 2020 rates for states, the District of Columbia, and Puerto Rico were obtained from U.S. Census Annual Estimates of the Resident Population for the United States, Regions, States, the District of Columbia and Puerto Rico (April 1, 2010 to July 1, 2020). Totals for U.S. territories were obtained from the International Data Base and totals for freely associated states were obtained from the United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019, Online Edition. Total Population (both sexes combined) by region, subregion and country, annually for 1950-2100 (thousands) Estimates, 1950 – 2020; accessed June 13, 2021.
See Technical Notes.
Double dashes (––) indicate that data are not available.Table Printing Tips
							
					
							Last Reviewed:  October 21, 2021						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue